Simple frameshifts in minimally invasive
surgery postoperative pain management
significantly reduce opiate prescriptions
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Introduction: To evaluate the impact of an “opt-in”
non-narcotic postoperative pain regimen on narcotic
utilization and patient-reported pain scores.
Materials and methods: A prospective, non-blinded preand post-interventional trial was conducted, including a
lead-in period for baseline evaluation. The intervention
group received a new pain protocol prioritizing nonnarcotic medications, an “opt-in” requirement for opiates,
and standardized patient education. Study outcomes
included opiate prescription and utilization (measured
in Morphine Equivalent Doses) and reported pain scores
on postoperative day (POD) 1, discharge and follow up.
Results: At discharge, 70% fewer patients were prescribed
any opioids (ARR: -0.7; p < 0.001); the amount prescribed

Introduction
The U.S. opioid crisis has risen to the forefront of the
medical community’s consciousness, partly due to the
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was reduced by 95% (pre-intervention 69.3 mg versus
post-intervention 3.5 mg, p < 0.001). Mean opioids used
following discharge decreased by 76% (14.7 mg versus
3.5 mg, p = 0.011). In a subgroup analysis of robotic
prostatectomies, there was a 95% reduction in mean opioids
prescribed at discharge (64.6 mg versus 3.2 mg, p < 0.001)
and 82% reduction in utilization over entire postoperative
course (87.6 mg versus 15.7 mg, p = 0.001). There was no
significant difference in pain scores between intervention
groups at POD 1, discharge and follow up for patients
(entire cohort and post-prostatectomy).
Conclusion: A standardized pain protocol with “opt-in”
requirements for opiate prescription, emphasis on nonnarcotic medications, and patient education, resulted in
significant reductions in opioid use. Simple frameshifts
in pain management can yield significant gains in the
opioid epidemic.
Key Words: narcotics, pain postoperative, minimally
invasive surgical procedures, urology

sharp rise in opioid use and abuse over the past two
decades.1 Many patients first encounter opioids as
part of standard postoperative pain management.2,3
Indeed, 1 in 16 surgical patients prescribed narcotics
become long term users, and 6% of opioid-naïve
surgical patients become newly addicted.2,3 Prescribing
opioids to surgical patients is particularly complicated
as clinicians must balance pain management against
the risk of abuse.4 As a result, there exists a significant
variation in physician prescription patterns, and
opioid-naïve and opioid-tolerant patients are at risk
for misuse, abuse, addiction, overdose, and diversion
that can accompany persistent opioid use.4,5
© The Canadian Journal of Urology™; 27(3); June 2020
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Minimally invasive surgery (MIS)
is increasingly popular with patients
and practitioners, offering decreased
postoperative morbidity, hospital
stay, costs and pain while maintaining
excellent surgical outcomes.6 Despite
these advantages, opioids are routinely
prescribed to patients undergoing MIS.
Knight et al found that similar amounts
of opioids were prescribed following open
inguinal hernia repairs and minimally
invasive repairs, and that patients were
not using significantly different amounts
of opioids based on surgical approach.7
Other studies of open and laparoscopic
surgeries on a general surgery service
found that less than one-third of opioids
prescribed were being consumed.8 When
one study instituted a restrictive opioid
prescribing protocol following gynecologic
oncology surgery, there was a reduction in
opioids prescribed in both the minimally
invasive cohort and the laparotomy cohort,
without an increase in refill requests or
difference in pain scores.9 Within the field
of urology, one prospective study showed
a median prescription of 27 oxycodone
equivalents following both minimallyFigure 1. Study design and endpoints. Patients in the first month
invasive nephrectomy and robotic-assisted
received the current pain protocol, with opioids automatically ordered.
laparoscopic prostatectomy, the majority
10,11
Patients in the second month received the novel pain protocol, which
of which went unused.
The PENN
required providers to “opt in” to prescribing.
cohort study - one of the only prospective
trials of a novel protocol to reduce opioid
use after urologic surgery - found that
two-thirds of patients undergoing MIS were able to be
opioid use were excluded. All remaining eligible
discharged without pain medications. They also found
patients were recruited during a lead-in period (June
that there were no differences in pain score between
2019) as the pre-intervention (PrI) group, Figure 1.
those who received opioids at discharge and those who
PrI participants received the established pain control
did not.12 Thus, reducing the utilization of opiates after
regimen, with opioids automatically prescribed as part
MIS appears to be a critical opportunity for mitigating
of an order set during the hospital course and at the
the opioid epidemic without sacrificing adequate pain
time of discharge. During the second month (July 2019),
control.7-13
all eligible patients were recruited to participate in the
In an effort to address this, we assessed the impact
post-intervention, PoI, group, Figure 1. These patients
of an “opt-in” postoperative pain protocol in an
were treated with a newly-designed pain protocol
interventional study of urologic oncology patients
aimed at reducing narcotic prescriptions. Notably, this
undergoing MIS at Thomas Jefferson University
protocol required prescribers to “opt-in” for opioid
Hospital, a tertiary care referral center in Philadelphia.
orders based on their assessment of a patient’s pain,
rather than automatically ordering them to be used as
Materials and methods
needed. The protocol also emphasized the prescription
of non-narcotic pain medications, such as NSAIDs or
Patients undergoing MIS on the urologic oncology
acetaminophen, as first-line therapy; opioids were
service over a 2-month period were identified for this
then made available if patients continued to have pain
IRB- approved study. Patients with a history of chronic
after receiving first-line medications. Patients were
© The Canadian Journal of Urology™; 27(3); June 2020
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Figure 2. SmartPhrase for postsurgical discharge instructions.
prescribed opiates at discharge only if they required
opioids in the 24 hours prior to discharge, and were
provided educational materials on pain management
expectations in their discharge instructions, Figure 2.
To evaluate the efficacy of this new protocol, primary
endpoints included patient numerical rating scale
(NRS) pain scores as well as opioid use at postoperative
day 1 (POD1), discharge, and follow up. Secondary
endpoints included prescription and usage of opiates
over the entire surgical course for both groups. This
was recorded in morphine equivalent doses (MED).
Geometric means were calculated for MED at each time
point. T-tests of logarithmic data were performed for
MED comparisons (alpha- level: 0.05), and the MannWhitney test of significance for non-parametric data
was used for NRS pain scores.14 Data analyses were
performed using SAS 9.4. We hypothesized there would
be no difference in patient-reported pain at POD1,
discharge or follow up between the two pain protocols.

by the same five urologic oncologists. A total of 21
participants were recruited to the PrI group; one
additional patient was excluded due to a history of
opioid abuse. Thirty-one patients were approached
to participate in the PoI group; 1 declined and 30 were
recruited. The PrI group and PoI were demographically
similar (mean age: 61.8 versus 59.9 years; percent
of male patients: 86% versus 83%, respectively).
Sixteen patients in the PrI group underwent robotic
prostatectomies, 4 received robotic nephrectomies, and
1 underwent another MIS procedure. Of the patients in
the PoI group, 21 underwent robotic prostatectomies, 6
received nephrectomies (1 laparoscopic and 5 robotic),
and 3 underwent another type of MIS. The mean time
to follow up in PrI was 11.9 days (range: 5-29 days,
SD: 6.1 days) and 9.9 days in the PoI (range: 6-21 days,
SD: 3.4 days). One patient in the PoI group was lost
to follow up after discharge.

Results

The mean MED during the postoperative period in the
PoI group was 16.9 mg compared to 15.2 mg in the PrI
group (p = 0.845). At the time of discharge, there was
a 70% reduction (ARR: -0.7, p < 0.001, 95% CI [-0.86
to -0.54]) in the number of patients prescribed any

Demographics

Patient demographics are provided in Table 1.
Surgeries for each intervention group were performed
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General cohort
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TABLE 1. Characteristics of intervention groups
		
Overall (n = 51)
Prl (n = 21)
Pol (n = 30)
Age, mean (SD)

60.7 (10.0)

61.8 (10.6)

59.9 (9.6)

EBL (mL, mean (SD))

266.2 (194.9)

254.8 (164.2)

274.2 (216.2)

LOS (days, mean (SD))

1.5 (1.1)

1.4 (0.9)

1.6 (1.3)

Interval from discharge to
follow up (days, mean (SD))

10.7 (4.8)

11.9 (6.1)

9.9 (3.4)

Gender, n (%)
Male
Female

43 (84.3%)
8 (15.7%)

18 (85.7%)
3 (14.3%)

25 (83.3%)
5 (16.7%)

Race, n (%)
White/Caucasian
Black/African American
Hispanic
Asian

32 (62.8%)
14 (27.5%)
4 (7.8%)
1 (2.0%)

10 (47.6%)
9 (42.9%)
2 (9.5%)
0 (0.0%)

22 (73.3%)
5 (16.7%)
2 (6.7%)
1 (3.3%)

Primary condition, n (%)
Prostate cancer
Bladder cancer
Others

37 (72.5%)
2 (3.9%)
12 (23.5%)

16 (76.2%)
1 (4.8%)
4 (19.0%)

21 (70.0%)
1 (3.3%)
8 (26.7%)

Surgery performed, n (%)
Robotic prostatectomy
Minimally invasive nephrectomy
Others

37 (72.5%)
10 (19.6%)
4 (7.8%)

16 (76.2%)
4 (19.0%)
1 (4.8%)

21 (70.0%)
6 (20.0%)
3 (10.0%)

Prl = pre-intervention; PoI = post-intervention; SD = standard deviation; EBL = estimated blood loss; LOS = length of stay

opioids; in patients prescribed opioids, there was a 95%
decrease in the amount prescribed between groups
(PrI 69.3 mg versus PoI 3.5 mg, p < 0.001), Table 2.
Two patients in the PrI group requested opioids after
discharge, compared to three in the PoI group. There
was a 76% reduction in mean MED used by patients
in this period following discharge (PrI 14.7 mg versus
PoI 3.5 mg, p = 0.011), Table 2. Total mean values of
opioids prescribed (postoperative, discharge, and
additional amounts requested by patients at home)
and opioids used by patients were compared between
the PrI and PoI groups, revealing a 77% reduction
in MED prescribed (p = 0.002) and a 42% reduction
in MED used (p = 0.327). The mean NRS pain score
at POD1, discharge and follow up visit were 4.0, 3.6
and 1.5 in the PrI group, and 4.5, 4.1 and 1.6 in the
PoI group, respectively. There was no significant
difference in pain at each time point between groups,
Table 2; Figure 3.

Robotic-assisted laparoscopic prostatectomy cohort

A subset analysis was performed on the 37 patients
who underwent robotic prostatectomies (RALP), as
© The Canadian Journal of Urology™; 27(3); June 2020

this remains the most common MIS procedure within
urologic oncology and of unique interest. In the PrI
group, mean length of stay was 1 day (SD: 0 days), and
1.05 (SD: 0.22 days) in the PoI group (p = 0.390, 95%

Figure 3. Mean NRS pain scores over the surgical course
in the general cohort. There was no difference in NRS
pain scores between the pre- and post-intervention
groups at POD1, discharge or follow up.
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TABLE 2. Group mean MED and NRS
		
Prl (n = 21)
Pol (n = 30)

		
p valuea

Postoperative
Patients receiving narcotics, n (%)
MED (mg, meanb [95% CIb])
MED (mg, median (Q1-Q3))
NRS pain score, mean (SD), [95% CI]

15 (71.4%)
15.2 [6.4, 36.1]
32.5 (0-56)
4.0 (2.8), [2.8, 5.3]

23 (76. 7%)
16.9 [8.5, 33.6]
26.3 (7.5-67.5)
4.5 (3.0), [3.3, 5.6]

0.673
0.845

Discharge
Patients discharged on narcotics, n (%)
MED (mg, meanb [95% CIb])
MED (mg, median (Q1-Q3))
NRS pain score, mean (SD), [95% CI]

21 (100.0%)
69.3 [60.0, 80.2]
75 (60-75)
3.6 (2.6), [2.4, 4.7]

9 (30.0%)
3.5 [1.7, 7.4]
0 (0-37.5)
4.1 (2.6) , [3.1, 5.1]

< 0.001
< 0.001

Follow up
Patients receiving additional narcotics, n (%)
MED (mg, meanb [95% CIb])
MED (mg, median (Q1-Q3))
NRS pain score, mean (SD), [95% CI]

2 (9.5%)
14.7 [5.9, 36.7]
37.5 (0-60)
1.5 (2.1), [0.5, 2.4]

3 (10.3%)
3.5 [1.7, 7.0]
0 (0-30)
1.6 (2.6) , [0.6, 2.6]

0.924
0.011

MED over entire surgical course
Prescribed (mg, meanb [95% CIb])
Used (mg, meanb [95% CIb])

103.0 [79.9, 132.7]
35.8 [15.1, 84.9]

23.3 [10.9, 49.8]
20.9 [10.1, 43.1]

0.002
0.327

0.752

0.597

0.759

p value corresponds to t-test of logged data for MED variables, Mann-Whitney test for continuous variables (NRS pain scores),
and χ2 test for categorical variables
b
geometric mean and its 95% confidence interval
MED = morphine equivalent doses; SD = standard deviation; CI = confidence interval; Q1 = lower quartile; Q3 = upper quartile;
NRS = numerical rating scale
a

CI [-0.16 to -0.06]). Ten of 16 patients in the PrI group
received opioids in the postoperative period, compared
to 15 of 21 in the PoI group. Neither the number of
patients receiving opioids nor the mean amount of
opioids received during this period was significantly
different between the two groups, Table 3; p = 0.565
and 0.792, respectively). However, at discharge, there
was a significant difference in patients who were
prescribed opioids: 100% of patients in the PrI group
were discharged with opioids, compared to 29% in the
PoI group (16 versus 6 patients, ARR: -0.71, p < 0.001,
95% CI [-0.91 to -0.52]). PrI patients also received
significantly more opioids at discharge (64.6 mg PrI
versus 3.2 mg PoI, p < 0.001). Two patients required
additional opioids at the time of follow up, both of
whom were in the PoI group (p = 0.288) and who
received a mean MED of 1.5 mg (0 mg PrI versus 1.5 mg
PoI, p = 0.163). For patients undergoing prostatectomy,
we found that there was an 82% reduction in the
amount of opioids prescribed over the entire surgical
course between the PrI and PoI group (87.6 mg versus
15.7 mg, p = 0.001). Mean amount of opioids used
by patients over surgical course was reduced by 42%
from pre-intervention to post-intervention; however,
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there was not a significant difference between the two
groups (24.2 mg PrI versus 13.7 mg PoI, p = 0.367). Pain
scores measured on postoperative day 1, discharge and
follow up were not significantly different between the
pre- and post- intervention groups, Table 3.

Discussion
Postoperative narcotics remain a significant source of
opiate exposure for MIS patients and an opportunity
for improvements in clinical prescribing habits. Our
single-institution study, which is one of the first
prospective trials to evaluate postoperative pain
control and patient-reported outcomes, demonstrated
that a standardized pain protocol with an “opt-in”
requirement for prescription of opiates, non-narcotic
medications as the first line for pain control, and
patient education, had a significant impact on opioid
use in postoperative patients. Firstly, analyses of the
entire cohort and the prostatectomy cohort found
that approximately 70% of patients in the PoI group
were discharged without any narcotic prescription.
These results are similar to the 67.7% reduction
found by Talwar et al. 12 In our general cohort,
© The Canadian Journal of Urology™; 27(3); June 2020
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TABLE 3. Radical prostatectomy subgroup analysis
		
Prl (n = 16)
Pol (n = 21)
Postoperative
Patients receiving narcotics, n (%)
10 (62.5%)
15 (71.4%)
MED (mg, meanb [95% CIb])
9.2 [3.4, 25.3]
10.8 [5.1, 23.1]
MED (mg, median (Q1-Q3))
20 (0-46.3)
20 (0-38.8)
NRS pain score, mean (SD), [95% CI]
3.1 (2.3), [1.8, 4.3]
3.6 (2.7), [2.4, 4.8]
Discharge
Patients discharged on narcotics, n (%)
MED (mg, meanb [95% CIb])
MED (mg, median (Q1-Q3))
NRS pain score, mean (SD), [95% CI]

16 (100.0%)
64.6 [56.2, 74.1]
75 (60-75)
3.1 (2.5), [1.7, 4.4]

6 (28.6%)
3.2 [1.4, 7.7]
0 (0-38.8)
3.7 (2.7), [2.5, 4.9]

		
p valuea
0.565
0.792
0.721
< 0.001
< 0.001
0.598

Follow up
Patients receiving additional narcotics, n (%)
0 (0%)
MED (mg, meanb [95% CIb])
MED (mg, median (Q1-Q3))		
NRS pain score, mean (SD), [95% CI]
1.1 (1.8), [0.2, 2.1]

2 (9.5%)		0.288
1.5 [0.8, 2.7]
0.163
1.0 (1.5), [0.3, 1.7]
0.700

MED over entire surgical course
Prescribed (mg, meanb [95% CIb])
Used (mg, meanb [95% CIb])

15.7 [6.4, 38.7]
13.7 [6.0, 31.3]

87.6 [70.5, 108.8]
24.2 [8.6, 68.2]

0.001
0.367

p value corresponds to t-test of logged data for MED variables, Mann-Whitney test for continuous variables (NRS pain scores),
and χ2test for categorical variables
b
geometric mean and its 95% confidence interval
MED = morphine equivalent doses; SD = standard deviation; CI = confidence interval; Q1 = lower quartile; Q3 = upper quartile;
NRS = numerical rating scale
a

there were significant reductions in the amount of
opioids prescribed at discharge, the amount used
during follow up, and the overall amount of opioids
prescribed over surgical course in the PoI group.
Importantly, we found that there was no difference in
the number or amount of narcotics prescribed in the
postoperative period between the PrI and PoI groups.
This indicates that patients experience significant
pain in the postoperative period that may require
narcotics. However, when considered in combination
with the significant difference in opioid prescription
at discharge (secondary to the “24 hour rule” of the
intervention) between PrI and PoI, it becomes clear
that patients generally do not need to be sent home
with an opioid prescription. This is consistent with
previous studies that found that the majority of
discharge narcotics were not utilized.8,10,11 The results
of this intervention highlight a targeted approach to
narcotic prescription reduction: while patients may
need narcotics initially, it is appropriate to discontinue
or significantly reduced these medications at discharge
without compromising patient comfort.
In this study’s prostatectomy cohort, there were
similarly significant reductions in the amount of
© The Canadian Journal of Urology™; 27(3); June 2020

opioids prescribed at discharge and over the entire
surgical course. RALP procedures often result in a
hospitalization of 1 day; despite this, many patients were
able to be discharged without narcotic prescriptions, as
they had not required narcotics in the preceding 24
hours. This seeming discrepancy is likely due to the
differing nature of these calculations: length of stay
was recorded as a whole number (thus not reflecting a
portion of a day stayed), while a provider deciding to
prescribe narcotics was able to specifically look at the
past 24 hours in a patient’s chart at discharge. These
results reflect the importance of the “24-hour” rule, as
it allows providers to base narcotic prescriptions on a
more accurate picture of a patient’s needs.
Finally, and most importantly, the reductions noted
in each analysis were not associated with any significant
difference in pain scores at any time point between the
pre- and post- intervention group. While the PENN
study also found no significant difference in pain
between patients discharged with and without opioids,12
it is difficult to make further comparisons, as there was
not a pre- and post- intervention analysis of opioid
prescribing habits or pain scores. Similarly, the ORIOLES
study15 found that a three-part intervention resulted
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changes in prescribing habits without a difference in
postoperative pain; however, the study evaluated only
the presence of incisional/post-surgical pain at 30 days,
rather than evaluating differences in patient pain ratings
at multiple time intervals soon after surgery.
This study indicates that many MIS patients can
be prescribed non-narcotic pain medication in the
post-surgical period without negatively affecting pain
control. We believe the “opt-in” requirement for opiates
accounts for the dramatic decrease in prescription over
patients’ entire surgical course between the two groups.
This requirement - while an additional step for health
care professionals - provides a vital period of reflection
on the benefits versus risks of opiates in individual
patients, and acts as a “check” on their prescription.
Equally important appears to be the “24-hour” rule,
where patients in the PoI group only receive opiates at
discharge if required in their final 24 hours of inpatient
care. We posit that this accounts for the dramatic
decrease in opioids prescribed at discharge. Our results
also show that while a few patients required additional
narcotic prescriptions between discharge and follow
up, the majority did not. Surgeons can be reassured
by this- most patients will not be in pain and unable
to access medications to make themselves comfortable
(a commonly cited concern and reason for significant
prescriptions at discharge). Finally, we believe that
patient education in the form of standardized discharge
instructions is critical to empowering patients and
increasing their knowledge. Anecdotal reports from
participants in the study cited the discharge instructions
as being a helpful way to gauge the “appropriateness”
of their pain.
Limitations to this study include the small sample
size and the use of a subjective pain scale. Additionally,
this study was subject to recall bias. Although the
majority of patients brought in their narcotics pills for
a pill count (as instructed in the discharge paperwork),
a few patients relied on memory when reporting how
many they had taken. Further studies are necessary
to continue to evaluate the efficacy of this protocol in
larger, more diverse surgical cohorts. The effectiveness
of patient education on pain expectations should be
investigated and optimized. Finally, the applicability
of this protocol to other types of minimally invasive
cases outside the field of urologic oncology should be
examined.

Conclusion
The opioid epidemic is a national healthcare emergency
that warrants increased physician engagement. With
a growing understanding of the personal and societal
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cost of opioid addiction, surgeons must participate in
policy changes to help reduce opiate use. This study
highlights the importance of patient education and an
“opt-in” model of postoperative pain management in
significantly reducing opiate utilization.
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